| Identification | More | [Name]
Hydroxypropyl methylcellulose phthalate | [CAS]
9050-31-1 | [Synonyms]
HPMCP
HYDROXYPROPYL METHYL CELLULOSE PHTHALATE
HYDROXYPROPYL METHYLCELLULOSE PHTHALATE 50
HYDROXYPROPYL METHYLCELLULOSE PHTHALATE 55
2-hydroxypropylmethylcellulosephthalate
Cellulose,hydrogen1,2-benzenedicarboxylate,2-hydroxypropylmethylether
cellulosephthalatehydroxypropylmethylether
hp55
hp55f
Hydroxy Propyl Methyl Celluose Phthalate
HYDROXYPROPYL METHYL CELLULOSE PHTHALAT&
Methylhydroxypropylcellulosephthalate
Hydroxypropylmethylcellulosephtalat
HYDROXY PROPYL METHYL CELLULOSE PTHALATE | [EINECS(EC#)]
232-674-9 | [Molecular Formula]
(C36H44O19)N | [MDL Number]
MFCD00147216 | [MOL File]
9050-31-1.mol | [Molecular Weight]
240.304 |
| Chemical Properties | Back Directory | [Appearance]
White to off-white free-flowing flakes or granules | [Melting point ]
>145 °C (dec.)(lit.)
| [density ]
0.6 g/mL at 25 °C(lit.)
| [storage temp. ]
2-8°C | [solubility ]
H2O: Limited solubility at low pH, soluble at pH ≥4.2.soluble
| [form ]
neat | [Stability:]
Stable under recommended storage conditions., Stable Under Recommended Storage C | [Major Application]
pharmaceutical (small molecule) | [Cosmetics Ingredients Functions]
ORAL CARE | [InChI]
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) | [InChIKey]
DOUYETYNHWVLEO-UHFFFAOYSA-N | [SMILES]
N1(C([H])=NC2C(N([H])[H])=NC3=C([H])C([H])=C([H])C([H])=C3C1=2)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] | [CAS DataBase Reference]
9050-31-1(CAS DataBase Reference) | [EPA Substance Registry System]
9050-31-1(EPA Substance) |
| Hazard Information | Back Directory | [Chemical Properties]
White to off-white free-flowing flakes or granules | [Uses]
(Hydroxypropyl)methyl Cellulose Phthalate is a therapeutic compound and methods of colesevelam. | [Definition]
ChEBI: Imiquimod is an imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. It has a role as an antineoplastic agent and an interferon inducer. | [Production Methods]
Hypromellose phthalate is prepared by the esterification of
hypromellose with phthalic anhydride. The degree of alkyloxy
and carboxybenzoyl substitution determines the properties of the
polymer and in particular the pH at which it dissolves in aqueous
media. | [Pharmaceutical Applications]
Hypromellose phthalate is widely used in oral pharmaceutical
formulations as an enteric coating material for tablets or
granules. Hypromellose phthalate is insoluble in gastric fluid
but will swell and dissolve rapidly in the upper intestine. Generally,
concentrations of 5–10% of hypromellose phthalate are employed
with the material being dissolved in either a dichloromethane : ethanol
(50 : 50) or an ethanol : water (80 : 20) solvent mixture.
Hypromellose phthalate can normally be applied to tablets and
granules without the addition of a plasticizer or other film formers,
using established coating techniques. However, the addition of a
small amount of plasticizer or water can avoid film cracking
problems; many commonly used plasticizers, such as diacetin,
triacetin, diethyl and dibutyl phthalate, castor oil, acetyl monoglyceride,
and polyethylene glycols, are compatible with hypromellose
phthalate. Tablets coated with hypromellose phthalate
disintegrate more rapidly than tablets coated with cellulose acetate
phthalate.
Hypromellose phthalate can be applied to tablet surfaces using a
dispersion of the micronized hypromellose phthalate powder in an
aqueous dispersion of a suitable plasticizer such as triacetin, triethyl
citrate, or diethyl tartrate together with a wetting agent.
Hypromellose phthalate may be used alone or in combination
with other soluble or insoluble binders in the preparation of
granules with sustained drug-release properties; the release rate is
pH-dependent. Since hypromellose phthalate is tasteless and
insoluble in saliva, it can also be used as a coating to mask the
unpleasant taste of some tablet formulations. Hypromellose
phthalate has also been co-precipitated with a poorly soluble drug
to improve dissolution characteristics. | [Safety]
Hypromellose phthalate is widely used, primarily as an enteric
coating agent, in oral pharmaceutical formulations. Chronic and
acute animal feeding studies on several different species have shown
no evidence of teratogenicity or toxicity associated with hypromellose
phthalate.Hypromellose phthalate is generally regarded
as a nonirritant and nontoxic material. | [storage]
Hypromellose phthalate is chemically and physically stable at
ambient temperature for at least 3–4 years and for 2–3 months at
40°C and 75% relative humidity. It is stable on exposure to UV
light for up to 3 months at 25°C and 70% relative humidity. Drums
stored in a cool, dry place should be brought to room temperature
before opening to prevent condensation of moisture on inside
surfaces. After 10 days at 60°C and 100% relative humidity, 8–9% of carbyoxybenzoyl group were hydrolyzed. In general, hypromellose
phthalate is more stable than cellulose acetate phthalate. At
ambient storage conditions, hypromellose phthalate is not susceptible
to microbial attack. | [Incompatibilities]
Incompatible with strong oxidizing agents.
Splitting of film coatings has been reported rarely, most notably with coated tablets that contain microcrystalline cellulose and calcium carboxymethyl cellulose. Film splitting has also occurred when a mixture of acetone : propan-2-ol or dichloromethane : propan- 2-ol has been used as the coating solvent, or when coatings have been applied in conditions of low temperature and humidity. However, film splitting may be avoided by careful selection of formulation composition, including solvent, by use of a higher molecular weight grade of polymer, or by suitable selection of plasticizer.
The addition of more than about 10% titanium dioxide to a coating solution of hypromellose phthalate, which is used to produce a colored film coating, may result in coating with decreased elasticity and resistance to gastric fluid.
| [Regulatory Status]
Included in the FDA Inactive Ingredients Database (oral capsules
and tablets). Included in nonparenteral medicines licensed in the
UK. Included in the Canadian List of Acceptable Non-medicinal
Ingredients. |
| Safety Data | Back Directory | [Safety Statements ]
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
1
| [RTECS ]
FJ5954000
| [TSCA ]
TSCA listed | [HS Code ]
39129090 | [Storage Class]
11 - Combustible Solids |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
|